Table S3. from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• Analysis indicates significant differences in tumor fraction in F1LCDx−/CTA+ and F1LCDx+/CTA− subsets.
• Findings reveal the potential impact of foundationone liquid cdx for detecting braf v600e in colorectal cancer.
• Study highlights the importance of precise tumor fraction assessment in colorectal cancer diagnostics.
• Data demonstrates how rising tumor fractions could improve the detection accuracy for braf v600e alterations.